Malin Life Sciences Holdings Ltd 4
4 · Poseida Therapeutics, Inc. · Filed Jan 10, 2025
Insider Transaction Report
Form 4
Malin Life Sciences Holdings Ltd
10% Owner
Transactions
- Disposition from Tender
COMMON STOCK
2025-01-08−11,835,673→ 0 total
Footnotes (2)
- [F1]Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent ("Merger Sub"). On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $9.00 per Share in cash (the "Cash Amount"), and (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2]
- [F2][continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). Pursuant to and in connection with that certain Tender and Support Agreement (the "Tender and Support Agreement"), dated November 25, 2024, by and among the reporting person, Parent and Merger Sub, entered into in connection with the Merger Agreement, these shares of common stock, par value $0.0001 per share were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price.